Breast carcinoma and plasma 17-beta-estradiol binding

Area of Science:

• Endocrinology
• Oncology
• Biochemistry

Background:

• Data on plasma steroid binding and transport, particularly dehydrotestosterone, remain controversial.
• Estradiol (E2) binding in plasma is a key factor in steroid transport and has been implicated in various physiological and pathological conditions.

Purpose of the Study:

• To investigate and compare plasma E2 binding levels in breast carcinoma patients versus healthy controls.
• To evaluate the potential of E2 binding as a diagnostic marker for breast cancer.

Main Methods:

• Plasma samples from 79 breast carcinoma patients and 46 controls were analyzed.
• Endogenous steroids were removed using charcoal treatment.
• Plasma was incubated with 17-beta-estradiol (E2) under non-saturating conditions.
• Ammonium sulfate precipitation was used to isolate the E2-binding complex.

Main Results:

• Plasma E2 binding was significantly increased (P < 0.01) in both premenopausal (85 ± 11 pg/ml) and postmenopausal (73 ± 13 pg/ml) breast carcinoma patients compared to controls (premenopausal: 59 ± 7 pg/ml; postmenopausal: 58 ± 5 pg/ml).
• The study noted a low percentage of false-positives and false-negatives in the assay.

Conclusions:

• Elevated plasma E2 binding is observed in breast carcinoma patients.
• The increased E2 binding could represent either a primary increase in binding capacity or a host response to sequester excess estradiol.
• Plasma E2 binding shows potential as a tumor marker for breast carcinoma detection.